2상모집 중

Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial

연구 개요

Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.

스폰서: 협력: BMS
적응증: Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance
중재: Enasidenib
목표 등록: 15명
시작일: 2024-10-10
완료(예정): 2029-02-28
등록번호: NCT06240754 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.